• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

HER2- Mutation Testing Considerations and Timing

Opinion
Video

Panelists discuss how integrating HER2-directed therapies into existing NSCLC decision-making processes presents challenges, focusing on strategies for timely updates as new therapies emerge and the practicalities of HER2- mutation testing, including turnaround times and result interpretation for therapy selection.

Related Videos
Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.